Roche (RHHBY) said FDA has approved Vabysmo (faricimab-svoa) for the treatment of neovascular or "wet" age-related macular degeneration and diabetic macular edema. Neovascular AMD and DME are two leading causes of vision loss worldwide. The company noted that Vabysmo is the first and only FDA-approved injectable eye medicine for nAMD and DME that improves and maintains vision with treatments from one to four months apart in the first year following four initial monthly doses.
"Vabysmo provides a new approach to treating vision-threatening retinal conditions through a mechanism of action that targets two pathways simultaneously," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
Vabysmo will be available in the United States in the coming weeks, Roche said.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.